Rapid Micro Biosystems director exercises options for 3,508 shares

Q: What insider transaction did Richard S. Kollender report for RPID?

Richard S. Kollender, a director of Rapid Micro Biosystems (RPID), reported exercising stock options on 2026-07-24. The transactions converted options into 3,508 shares of Class A Common Stock through two separate exercises disclosed in the Form 4 data.

Q: How many shares were acquired and at what price in the RPID Form 4?

Kollender acquired 3,508 shares of Rapid Micro Biosystems Class A Common Stock by exercising options at an exercise price of $0.7500 per share. The exercises occurred in two tranches of 1,681 and 1,827 shares on the same date.

Q: What type of securities were involved in Richard Kollender’s RPID insider transaction?

The transactions involved Stock Option (Right to Buy) derivative securities that converted into Class A Common Stock. Two option positions were exercised, each delivering the same number of underlying shares as the options exercised, at a stated exercise price of $0.7500 per share.

Q: Were the options exercised by the RPID director fully vested?

Yes. A footnote states that the option is fully vested and exercisable. This note applies to the reported option positions that were exercised, indicating there were no remaining vesting conditions at the time of the 2026-07-24 exercises.

Rapid Micro Biosystems, Inc. director Richard S. Kollender reported exercising stock options covering a total of 3,508 shares of Class A Common Stock on 2026-07-24.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Rapid Micro Biosystems, Inc. director Richard S. Kollender reported exercising stock options covering a total of 3,508 shares of Class A Common Stock on 2026-07-24. The options, described as fully vested and exercisable, were exercised at an exercise price of $0.7500 per share in two tranches of 1,681 and 1,827 underlying shares.

Insider Trade Summary

3,508 shares exercised/converted

Exercise 4 txns

Insider Kollender Richard S

Role Director

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy) ^F1	1,681	$0.00	$0.00
Exercise	Stock Option (Right to Buy) ^F1	1,827	$0.00	$0.00
Exercise	Class A Common Stock	1,681	$0.75	$1K
Exercise	Class A Common Stock	1,827	$0.75	$1K

Holdings After Transaction: Stock Option (Right to Buy) — 0 contracts (Direct); Class A Common Stock — 133,826 shares (Direct)

Footnotes (1)

F1. The option is fully vested and exercisable.

Key Figures

Options exercised: 3508 shares First option tranche: 1681 shares Second option tranche: 1827 shares +2 more

5 metrics

Options exercised 3508 shares Total underlying Class A Common Stock from options exercised on 2026-07-24

First option tranche 1681 shares Underlying Class A Common Stock from one Stock Option (Right to Buy) exercise

Second option tranche 1827 shares Underlying Class A Common Stock from the second Stock Option (Right to Buy) exercise

Exercise price $0.7500 per share Conversion or exercise price for the Stock Option (Right to Buy) positions

Option expiration date 2026-08-11 Expiration date for the exercised stock options

Key Terms

Stock Option (Right to Buy), Class A Common Stock, Exercise or conversion of derivative security, fully vested and exercisable

4 terms

Stock Option (Right to Buy) financial

"Transaction security title is Stock Option (Right to Buy)"

Class A Common Stock financial

"Underlying security title is Class A Common Stock"

Class A common stock is a category of a company’s shares that carries a specific set of ownership rights—most commonly defined voting power and claims on dividends—set out in the company’s charter. For investors it matters because the class determines how much influence you have over corporate decisions, the share’s likely dividend and trading behavior, and how it compares in value to other share classes, like choosing a particular seat with different privileges at the company’s decision-making table.

Exercise or conversion of derivative security financial

"Transaction code M is described as Exercise or conversion of derivative security"

fully vested and exercisable financial

"A footnote states the option is fully vested and exercisable"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Richard S. Kollender report for RPID?

Richard S. Kollender, a director of Rapid Micro Biosystems (RPID), reported exercising stock options on 2026-07-24. The transactions converted options into 3,508 shares of Class A Common Stock through two separate exercises disclosed in the Form 4 data.

How many shares were acquired and at what price in the RPID Form 4?

Kollender acquired 3,508 shares of Rapid Micro Biosystems Class A Common Stock by exercising options at an exercise price of $0.7500 per share. The exercises occurred in two tranches of 1,681 and 1,827 shares on the same date.

What type of securities were involved in Richard Kollender’s RPID insider transaction?

The transactions involved Stock Option (Right to Buy) derivative securities that converted into Class A Common Stock. Two option positions were exercised, each delivering the same number of underlying shares as the options exercised, at a stated exercise price of $0.7500 per share.

Were the options exercised by the RPID director fully vested?

Yes. A footnote states that the option is fully vested and exercisable. This note applies to the reported option positions that were exercised, indicating there were no remaining vesting conditions at the time of the 2026-07-24 exercises.

When did the Rapid Micro Biosystems options exercised by Kollender expire?

For the exercised options, the Form 4 data shows an expiration date of 2026-08-11. These options were exercised on 2026-07-24, ahead of that expiration date, converting them into shares of Class A Common Stock at the stated exercise price.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 07/24/2026 - 06:31 PM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kollender Richard S

(Last)

(First)

(Middle)

C/O RAPID MICRO BIOSYSTEMS, INC.

25 HARTWELL AVENUE

(Street)

LEXINGTON

MASSACHUSETTS

02421

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
RAPID MICRO BIOSYSTEMS, INC. [ RPID ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/24/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Class A Common Stock	07/24/2026		M		1,681	A	$0.75	131,999	D
Class A Common Stock	07/24/2026		M		1,827	A	$0.75	133,826	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$0.75	07/24/2026		M			1,681	⁽¹⁾	08/11/2026	Class A Common Stock	1,681	$0	0	D
Stock Option (Right to Buy)	$0.75	07/24/2026		M			1,827	⁽¹⁾	08/11/2026	Class A Common Stock	1,827	$0	0	D

Explanation of Responses:

1. The option is fully vested and exercisable.

Remarks:

	/s/ Sean M. Wirtjes, Attorney-in-Fact for Richard S. Kollender	07/24/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR